Publication & Citation Trends
Publications
0 total
Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial. OA
Cited by 146
Semantic Scholar
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low‐dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis OA
Cited by 4
Semantic Scholar
Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older OA
Cited by 31
Semantic Scholar
Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study OA
Cited by 8
Semantic Scholar
IDDF2019-ABS-0210 Preliminary efficacy and safety of 8-week glecaprevir/pibrentasvir in patients with HCV genotype 1–6 infection and compensated cirrhosis: the EXPEDITION-8 study OA
Cited by 58
Semantic Scholar
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis OA
Cited by 42
Semantic Scholar
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection OA
Cited by 197
Semantic Scholar
294 - Retreatment of Patients who Failed Glecaprevir/Pibrentasvir Treatment for Hepatitis C Virus Infection
Cited by 1
Semantic Scholar
Research Topics
Hepatitis C virus research
(51)
HIV/AIDS drug development and treatment
(36)
Liver Disease Diagnosis and Treatment
(18)
Hepatitis B Virus Studies
(15)
Systemic Lupus Erythematosus Research
(12)
Affiliations
AbbVie (United States)
Abbott (United States)
Abbott Fund